BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17164589)

  • 21. Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
    Moon YW; Sohn JH; Choi HJ; Chang H; Park BW; Kim SI; Park S; Koo JS; Kim YT; Roh JK; Chung HC; Kim JH
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):425-31. PubMed ID: 20012956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
    Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP
    Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential vinorelbine-capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial.
    Ghosn M; Kattan J; Farhat F; Younes F; Nasr F; Moukadem W; Gasmi J; Chahine G;
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):11-8. PubMed ID: 17717668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines.
    Vici P; Di Lauro L; Sergi D; Foggi P; Viola G; Mottolese M; Giotta F; Fattoruso SI; Corsetti S; Giannarelli D; Botti C; Lopez M
    Oncology; 2008; 75(3-4):175-81. PubMed ID: 18841031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-survival in responding patients with metastatic breast cancer treated with doxorubicin-docetaxel combination. A multicentre phase II trial.
    Mattioli R; Lippe P; Massacesi C; Cappelletti C; Nacciarriti D; Bisonni R; Graziano F; Menichetti ET; Imperatori L; Testa E; Laici G; Balletra A; Silva RR
    Anticancer Res; 2004; 24(5B):3257-61. PubMed ID: 15510620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer.
    Vassilomanolakis M; Koumakis G; Barbounis V; Demiri M; Panopoulos C; Chrissohoou M; Apostolikas N; Efremidis AP
    Breast; 2005 Apr; 14(2):136-41. PubMed ID: 15767183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer.
    Gómez-Bernal A; Cruz JJ; Olaverri A; Arizcun A; Martín T; Rodríguez CA; Martín G; Fonseca E; Sánchez P
    Anticancer Drugs; 2005 Jan; 16(1):77-82. PubMed ID: 15613908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
    Zhang J; Gu SY; Gan Y; Wang ZH; Wang BY; Guo HY; Wang JL; Wang LP; Zhao XM; Hu XC
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial.
    Park SH; Cho EK; Bang SM; Shin DB; Lee JH; Lee YD
    BMC Cancer; 2005 Feb; 5():21. PubMed ID: 15723709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP; Fossella F
    Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients.
    Ghosn M; Kattan J; Farhat F; Younes F; Gasmi J
    Anticancer Res; 2006; 26(3B):2451-6. PubMed ID: 16821631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma.
    Chua DT; Sham JS; Au GK
    Oral Oncol; 2005 Jul; 41(6):589-95. PubMed ID: 15975521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weekly combination of docetaxel and vinorelbine in metastatic breast cancer: a phase I/II study.
    Cals L; Nouyrigat P; Valenza B; Pedinelli FJ; Juin P
    Oncology; 2004; 67(3-4):257-61. PubMed ID: 15557787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatin.
    Polyzos A; Tsavaris N; Kosmas C; Polyzos K; Giannopoulos A; Felekouras E; Nikiteas N; Kouraklis G; Griniatsos J; Safioleas M; Stamatakos M; Pikoulis E; Papachristodoulou A; Gogas H
    Anticancer Res; 2006; 26(5B):3749-53. PubMed ID: 17094396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study.
    Bonneterre J; Campone M; Koralewski P; Blasinska-Morawiec M; Deporte-Fety R; Chatelut E; Leger F; Longerey B; Ecochard L; Douville I
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):365-73. PubMed ID: 17569044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study.
    Morales S; Lorenzo A; Ramos M; Ballesteros P; Méndez M; Almanza C; Castellanos J; Moreno-Nogueira JA; Casal J; Lizón J; Oltra A; Frau A; Machengs I; Galán A; Belón J; Llorca C
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):75-81. PubMed ID: 14557896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study.
    Esteban E; Modollel A; González de Sande L; Palacio I; Muñiz I; Fernández Y; Corral N; Fra J; Sala M; Vieitez JM; Estrada E; Lacave AJ;
    Breast Cancer Res Treat; 2003 Aug; 80(3):257-65. PubMed ID: 14503798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.